Astrocytoma, IDH-Mutant Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Astrocytoma, IDH-Mutant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 3

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

GliomaAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, Grade IV+5 more
Nuvation Bio Inc.365 enrolled45 locationsNCT05303519
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 1

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Recurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma
City of Hope Medical Center27 enrolled1 locationNCT06815029
Recruiting
Phase 1

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

GlioblastomaGBMGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc.66 enrolled8 locationsNCT05879367
Recruiting
Not Applicable

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

GlioblastomaAstrocytoma, IDH-Mutant, Grade 4
Amsterdam UMC, location VUmc30 enrolled1 locationNCT06623565